It is an honor to be recognized for our role in supporting the leading pharmaceutical companies of the world in their fight to combat this global pandemic.Dirk Lambrecht
BioNTech acknowledged the company’s historic achievement, highlighting the results of its Phase Three study, which demonstrated that the vaccine is well-tolerated and 95 percent effective in preventing COVID-19 after initiating development earlier in 2020. The vaccine has received conditional marketing authorizations as well as emergency use authorizations in more than 45 countries, including the United States and the European Union.
Datwyler has also been a partner of the Serum Institute of India, which has received emergency authorization of its vaccine, Covishield, in India. Serum Institute of India is the world's largest vaccine manufacturer by volume. It partnered with Oxford and other vaccine providers to produce one billion doses of the local version of their COVID-19 vaccine to serve the markets of India and Africa.
To support the leading vaccine providers of the world, Datwyler mobilized its global manufacturing resources, supplying vaccine components from its plants around the world, including those in the United States, Italy, Belgium, Germany and India. As demand surged for injectable drug packaging components such as the company’s OmniFlex® stoppers for vials and (PrimeCap™ aluminum seals—solutions to help protect the integrity of drug formulations against particulate contamination—Datwyler was prepared.
The company had already expanded its network of FirstLine® manufacturing facilities, which marry best-in-class production technologies with fully integrated cleanroom environments. The latest additions—a new (FirstLine® plant in Middletown, DE, US, and enlarged capacities at its Indian plant, provides critical infrastructure to support the increased demand around COVID-19. Datwyler also accelerated their timeline to scale-up production at their plants and shifted to a 24/7 schedule worldwide. This increased capacity for FirstLine® coated components significantly.
Moreover, to continue its efforts in supporting lead vaccine manufacturers and to avoid capacity shortages, Datwyler plans to invest CHF 75 million to CHF 85 million over the course of 2021 in additional production equipment at the existing seven healthcare plants on three continents as well as in the second production plant at the existing site in India.
We continue to optimize our facilities and have more investments in the pipeline. These measures not only ensure our ability to meet the escalating demands around COVID-19, but also help forge a new, more efficient path to the production of system-critical components for injectable drug packaging moving forward.Dirk Lambrecht